- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01369212
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (HBRN)
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of this study is to compare the long-term efficacy of treatment with combination therapy with peginterferon plus tenofovir versus tenofovir monotherapy in the treatment of chronic hepatitis B.
This is a randomized (1:1) parallel group design trial comparing (i) tenofovir disoproxil fumarate (TDF) 300 mg daily for 192 weeks (4 years) and (ii) peginterferon alfa-2a 180 µg weekly for 24 weeks plus Tenofovir DF 300 mg daily for 192 weeks (4 years). Enrolled participants will be stratified by HBeAg status (positive/negative), genotype (A vs. all others) and cirrhosis (present vs. absent). After 192 weeks of treatment, participants meeting criteria for treatment discontinuation will stop treatment and be followed for 48 weeks (total duration of treatment and follow up is 240 weeks). Emtricitabine/tenofovir coformulated as Truvada, approved for treatment of HIV but not for treatment of hepatitis B virus (HBV) infection, will be offered to patients with primary nonresponse, partial virological response or confirmed virologic breakthrough.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- University of Toronto-Toronto Western Hospital
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
San Francisco, California, United States, 94115
- California Pacific Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Queen's Medical Center
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- NIH Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55446
- University of Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
Saint Louis, Missouri, United States, 63104
- Saint Louis University
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
-
Virginia
-
Richmond, Virginia, United States, 23498
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
Seattle, Washington, United States, 98105
- University of Washington Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Participant is enrolled in the HBRN Cohort Study (NCT01263587) or completed the necessary components of the cohort baseline evaluation by the end of the baseline visit for this study
- 18 years or older
Chronic hepatitis B infection as evidenced by at least one of the following:
- HBsAg positive result within 8 weeks prior to randomization and another time at least 24 weeks prior to randomization with no HBsAg negative result in between.
- HBsAg positive within 8 weeks prior to randomization and HBV DNA ≥1000 IU/mL on 2 occasions at least 24 weeks apart (can include result from screening visit within 8 weeks of randomization)
- Hepatitis B e antigen positive or negative
- Serum HBV DNA ≥1000 IU/mL on 2 occasions at least 4 weeks apart within the 32 weeks prior to randomization (can include result from screening visit within 8 weeks of randomization)
- At least 2 elevated serum alanine aminotransferase (ALT) levels (> 30 U/L for males, >20 U/L for females) 4 weeks apart, and no more than 32 weeks apart, with the second being within 8 weeks of randomization
- Compensated liver disease
- No evidence of hepatocellular carcinoma (HCC)
- Liver biopsy done that shows findings consistent with chronic hepatitis B with histology activity index (HAI) ≥3 (necroinflammatory component only) or Ishak fibrosis score ≥1 or both, as assessed by the local study pathologist on review of a liver biopsy done within 144 weeks of randomization
- Females of child bearing potential must agree to use an adequate method of contraception throughout the study and must have a negative pregnancy test immediately prior to the start of treatment
Exclusion criteria:
- Serum ALT ≥450 U/L for males and ≥300 U/L for females
- Treatment with interferon or nucleos(t)ide analogues for hepatitis B within 48 weeks of randomization
- More than 48 weeks of therapy with nucleos(t)ide analogues for hepatitis B at any time in the past
- History of hepatic decompensation including but not limited to ascites, variceal bleeding, or hepatic encephalopathy
- Known allergy or intolerance to any of the study medications
- Females who are pregnant or breastfeeding
- Previous organ transplantation including engrafted bone marrow transplant
- Any other concomitant liver disease, including hemochromatosis, hepatitis C or D; Participants with severe steatohepatitis will be excluded (participants with non-alcoholic fatty liver disease [NAFLD] with steatosis only and/or mild to moderate steatohepatitis are acceptable)
- Positive anti-HIV
- Renal insufficiency with calculated (by Modification of Diet in Renal Disease (MDRD) method) creatinine clearance <60 mL/min within 8 weeks prior to randomization
- Platelet count <90,000 /mm3, hemoglobin <13 g/dL (males) or <12 g/dL (females), absolute neutrophil count <1500 /mm^3 (<1000/mm^3 for African-Americans) within 8 weeks prior to randomization
- History of active alcohol or drug abuse within 48 weeks of screening.
- Pre-existing psychiatric condition(s), including but not limited to: Current moderate or severe depression as determined by the study physician, history of depression requiring hospitalization within past 10 years, history of suicidal or homicidal attempt within the past 10 years, or history of severe psychiatric disorders including but not limited to schizophrenia, psychosis, bipolar disorder
- History of immune-mediated disease, or cerebrovascular, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, poorly controlled diabetes or uncontrolled seizure disorder
- Any medical condition that would be predicted to be exacerbated by therapy or that would limit study participation
- Any medical condition requiring or likely to require chronic systemic administration of corticosteroids or other immunosuppressive medications during the course of this study
- Evidence of active or suspected malignancy, or a history of malignancy within the last 144 weeks (except adequately treated carcinoma in situ or basal cell carcinoma of the skin)
- Need for ongoing use of any antivirals with activity against HBV during the course of the study
- Any other condition that in the opinion of the investigator would make the participant unsuitable for enrollment or could interfere with the participant participating in and completing the study.
- Participation in any other clinical trial involving investigational drugs within 30 days of randomization or intention to participate in another clinical trial during this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tenofovir
Tenofovir 192 weeks
|
300 mg daily for 192 weeks (4 years)
Other Names:
|
Experimental: Peginterferon-alfa 2a and tenofovir
A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
|
A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Participants With Hepatitis B Surface Antigen (HBsAg) Loss by Week 240
Time Frame: Week 240
|
Estimated percent of participants who became HBsAg negative by week 240 from randomization
|
Week 240
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Percent of Participants With HBsAg Loss at Week 192
Time Frame: Week 192
|
Cumulative percentage of participants with HBsAg loss at week 192 estimated using Kaplan-Meier method
|
Week 192
|
Number of Participants With Serious Adverse Events
Time Frame: Up to 240 weeks
|
Number of participants with at least one serious adverse event between randomization and week 240
|
Up to 240 weeks
|
Number of Participants With Adverse Events
Time Frame: up to 240 weeks
|
Number of participants with at least one adverse event between randomization and week 240
|
up to 240 weeks
|
Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 192
Time Frame: week 192
|
Number of participants who became Hepatitis B e antigen (HBeAg) negative at week 192 among HBeAg positive participants at randomization (baseline)
|
week 192
|
Number of Participants With HBeAg Loss at Week 240
Time Frame: week 240
|
Number of participants who became HBeAg negative at week 240 among HBeAg positive participants at baseline
|
week 240
|
Number of Participants With HBsAg Seroconversion at Week 192
Time Frame: week 192
|
Number of participants who became with HBsAg negative and developed anti-HBs at week 192
|
week 192
|
Number of Participants With HBsAg Seroconversion at Week 240
Time Frame: week 240
|
Number of participants who became HBsAg negative and developed anti-HBs at week 240
|
week 240
|
Number of Participants With HBeAg Seroconversion at Week 192
Time Frame: week 192
|
Number of participants who became HBeAg negative and developed anti-HBe at week 192 among HBeAg positive participants at baseline
|
week 192
|
Number of Participants With HBeAg Seroconversion at Week 240
Time Frame: week 240
|
Number of participants who became HBeAg negative and developed anti-HBe at week 240 among HBeAg positive participants at baseline
|
week 240
|
Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 192
Time Frame: week 192
|
Number of participants with normal alanine transaminase (ALT) levels at week 192 (Normal ALT for males ≤30 U/L, for females ≤20 U/L)
|
week 192
|
Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 240
Time Frame: week 240
|
Number of participants with normal alanine transaminase (ALT) levels [males ≤30 U/L, for females ≤20 U/L] at week 240
|
week 240
|
Number of Participants With HBV DNA<1000 IU/mL at Week 192
Time Frame: week 192
|
Number of participants with HBV DNA <1000 IU/mL at week 192
|
week 192
|
Number of Participants With HBV DNA<1000 IU/mL at Week 240
Time Frame: week 240
|
Number of participants with HBV DNA <1000 IU/mL at week 240
|
week 240
|
Number of Participants With HBV DNA<20 IU/mL at Week 192
Time Frame: week 192
|
Number of participants with HBV DNA<20 IU/mL at week 192
|
week 192
|
Number of Participants With HBV DNA<20 IU/mL at Week 240
Time Frame: week 240
|
Number of participants with HBV DNA<20 IU/mL at week 240
|
week 240
|
Absence of Detectable Antiviral Drug-Resistant HBV Mutations at Week 192
Time Frame: week 192
|
Absence of detectable antiviral drug-resistant HBV mutations at Week 192
|
week 192
|
Cumulative Percent of Participants With HBsAg Loss at Week 240
Time Frame: Week 240
|
Cumulative percent of participants with HBsAg loss at week 240 estimated using Kaplan-Meier method
|
Week 240
|
Number of Participants With Alanine Transaminase(ALT) Levels <= 38 U/L for Males and <=25 for Females at Week 192
Time Frame: week 192
|
Number of participants with alanine transaminase(ALT) levels <= 38 U/L for males and <=25 for females at week 192.
The cut-offs 38 and 25 are approximately 1.25 times the upper limit of normal (30 U/L for males and 20 U/L for females) respectively.
|
week 192
|
Collaborators and Investigators
Investigators
- Study Chair: Averell Sherker, MD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study Chair: Edward Doo, MD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator: Anna Lok, MD, University of Michigan
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Peginterferon alfa-2a
Other Study ID Numbers
- DK082864 HBRN Immune Active
- UL1RR024986 (U.S. NIH Grant/Contract)
- UL1TR001111 (U.S. NIH Grant/Contract)
- U01DK082864 (U.S. NIH Grant/Contract)
- U01DK082874 (U.S. NIH Grant/Contract)
- U01DK082944 (U.S. NIH Grant/Contract)
- U01DK082843 (U.S. NIH Grant/Contract)
- U01DK082871 (U.S. NIH Grant/Contract)
- UL1TR000004 (U.S. NIH Grant/Contract)
- A-DK-3002-001 (Other Grant/Funding Number: Interagency agreement with NIDDK)
- U01DK082863 (U.S. NIH Grant/Contract)
- U01DK082866 (U.S. NIH Grant/Contract)
- U01DK082867 (U.S. NIH Grant/Contract)
- U01DK082872 (U.S. NIH Grant/Contract)
- U01DK082919 (U.S. NIH Grant/Contract)
- U01DK082923 (U.S. NIH Grant/Contract)
- U01DK082927 (U.S. NIH Grant/Contract)
- U01DK082943 (U.S. NIH Grant/Contract)
- UL1TR000058 (U.S. NIH Grant/Contract)
- P30DK050306 (U.S. NIH Grant/Contract)
- M01RR000040 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
Ain Shams UniversityCompleted
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
Clinical Trials on Tenofovir
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
Mahidol UniversityRecruitingRenal Insufficiency | TenofovirThailand
-
French National Agency for Research on AIDS and...Gilead Sciences; PharmassetTerminatedHBe Negative Chronic Hepatitis B | Hepatitis B Viral InfectionFrance
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingHIV InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI... and other collaboratorsActive, not recruitingAdherence, Medication | Acceptability of Health CareSouth Africa, Zimbabwe
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed
-
Merck Sharp & Dohme LLCCompleted